Bio-Rad Laboratories, a life science research and clinical diagnostics product provider, announced the launch of the CFX Opus 96 Dx System and CFX Opus 384 Dx System on Oct. 20, 2021. These instruments provide real-time polymerase chain reaction (PCR) detection for in-vitro diagnostics (IVD) testing.
According to a company press release, the Opus 96 and OIpus 384 offer accurate and precise quantification to improve assay development and workflow efficiencies and productivity for diagnostic testing and research. Additionally, both are open systems that can multiplex up to five targets to provide IVD assay development and testing.
“We continue to see an increasing demand for real-time PCR systems that offer more efficient workflows and improved data management and analysis that meets regulatory requirements in IVD assay developm
ent and testing, and we’re pleased to introduce the [CFX] Opus Dx Detection Systems to meet these needs,” said Steven Blakely, director for Gene Expression and Software Technology, Bio-Rad, in the press release. “Both systems are robust and secure platforms that leverage Bio-Rad’s long-standing expertise in genomic tools to better serve both research and clinical diagnostic markets,” he added.
Both products have been listed with FDA for IVD testing and meets the requirement for IVD use in Europe. They are also registered with the regulatory bodies of Singapore and Canada.
